TY - JOUR
T1 - Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism
AU - Blazar, Bruce R
AU - Carreno, Beatriz M.
AU - Panoskaltsis-Mortari, Angela
AU - Carter, Laura
AU - Iwai, Yoshiko
AU - Yagita, Hideo
AU - Nishimura, Hiroyuki
AU - Taylor, Patricia A.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Acute graft-vs-host disease (GVHD) is influenced by pathways that can enhance or reduce lethality by providing positive or negative signals to donor T cells. To date, the only reported pathway to inhibit GVHD is the CTLA-4: B7 pathway. Because absence of the programmed death-1 (PD-1) pathway has been implicated in a predisposition to autoimmunity and hence a lack of negative signals, the effect of PD-1 pathway blockade on GVHD was explored using several distinct approaches. In each, GVHD lethality was markedly accelerated. Coblockade of CTLA-4 and PD-1 was additive in augmenting GVHD, indicating that these pathways are not fully redundant. Although neither perforin nor Fas ligand expression was required for GVHD enhancement, donor IFN-γ production was required for optimal GVHD acceleration in the absence of PD-1 ligation. These data indicate that PD-1 ligation down-regulates GVHD through modulation of IFN-γ production and suggest a novel therapeutic target for inhibiting GVHD lethality.
AB - Acute graft-vs-host disease (GVHD) is influenced by pathways that can enhance or reduce lethality by providing positive or negative signals to donor T cells. To date, the only reported pathway to inhibit GVHD is the CTLA-4: B7 pathway. Because absence of the programmed death-1 (PD-1) pathway has been implicated in a predisposition to autoimmunity and hence a lack of negative signals, the effect of PD-1 pathway blockade on GVHD was explored using several distinct approaches. In each, GVHD lethality was markedly accelerated. Coblockade of CTLA-4 and PD-1 was additive in augmenting GVHD, indicating that these pathways are not fully redundant. Although neither perforin nor Fas ligand expression was required for GVHD enhancement, donor IFN-γ production was required for optimal GVHD acceleration in the absence of PD-1 ligation. These data indicate that PD-1 ligation down-regulates GVHD through modulation of IFN-γ production and suggest a novel therapeutic target for inhibiting GVHD lethality.
UR - http://www.scopus.com/inward/record.url?scp=0041845131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041845131&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.171.3.1272
DO - 10.4049/jimmunol.171.3.1272
M3 - Article
C2 - 12874215
AN - SCOPUS:0041845131
SN - 0022-1767
VL - 171
SP - 1272
EP - 1277
JO - Journal of Immunology
JF - Journal of Immunology
IS - 3
ER -